Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   RG002C0106 Injection · Primary IgA Nephropathy

   Enrollment closed, study ongoing

   Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.·Phase 2· NCT07305974· Registry history of NCT07305974 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

2. Minor

   Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy…Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults

   Trial completed

   Also in this update: Final enrollment: 50 participants (planned 30)

   Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.·Phase 1· NCT06494527· Registry history of NCT06494527 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

3. Minor

   RG002C0106 Injection · Normal Renal Function and…RG002C0106 Injection · Normal Renal Function and Mild-to-Moderate Renal Impairment

   Trial status changed: Not Yet Recruiting → Active, Not Recruiting

   Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.·Phase 1· NCT07445906· Registry history of NCT07445906 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.